Saba Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Saba Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-131,005	Closed	-$1.85M	–	403
2024 Q1	$1.85M	Sell	131,005 -48,658	-27%	-$613K	0.03%	150
2023 Q4	$1.88M	Sell	179,663 -9,340	-5%	-$87.2K	0.04%	202
2023 Q3	$1.93M	Sell	189,003 -63,835	-25%	-$594K	0.05%	211
2023 Q2	$1.9M	Buy	252,838 +42,360	+20%	+$343K	0.05%	230
2023 Q1	$1.86M	Buy	210,478 +174,230	+481%	+$1.72M	0.04%	342
2022 Q4	$331K	Buy	+36,248	New	+$316K	﹤0.01%	560
2019 Q4	–	Sell	-40,187	Closed	-$276K	–	100
2019 Q3	$276K	Buy	+40,187	New	+$308K	0.01%	89

Other funds holding TEVA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

IAM

Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

SPC

Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Saba Capital Management's TEVA Position: Q2 2024 in Review

Saba Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q2 2024, closing a stake of 131,005 shares — an estimated $1.85M sold.

Saba Capital Management first reported a position in TEVA in Q3 2019 and held it in 7 quarters. The position peaked at $1.93M in Q3 2023. 533 funds tracked by Wall St. Rank hold TEVA as of Q2 2024.

Saba Capital Management reported no remaining Teva Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
Saba Capital Management sold 131,005 Teva Pharmaceuticals shares in Q2 2024, an estimated $1.85M.
Saba Capital Management first reported a position in Teva Pharmaceuticals in Q3 2019 and held it in 7 quarters.
Saba Capital Management's Teva Pharmaceuticals position peaked at $1.93M in Q3 2023.
533 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2024.

Based on Saba Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.